CagriSema vs Tirzepatide (Zepbound): Complete Head-to-Head Comparison
CagriSema vs Tirzepatide (Zepbound): Complete Head-to-Head Comparison
CagriSema and tirzepatide (Zepbound/Mounjaro) represent different approaches to next-generation obesity treatment. But there is a key fact that frames this entire comparison: they have been tested head-to-head, and tirzepatide won.
The REDEFINE 4 trial — the only direct comparison between these two medications — showed CagriSema produced 22.2% weight loss vs tirzepatide's 25.3% at 72 weeks. CagriSema did not meet the pre-specified non-inferiority endpoint. In the only fair, controlled comparison we have, tirzepatide was the better medication for weight loss.
That said, CagriSema has a distinct mechanism, a different side effect profile, and may offer unique advantages for certain patients. This guide covers everything you need to make an informed comparison.
Editorial Independence Note: Telehealth Ally does not accept payment from providers for placement or ranking. This comparison is based entirely on published clinical trial data. See our editorial policy for details.
Quick Comparison
| Factor | CagriSema | Tirzepatide (Zepbound) |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 + amylin analog | GLP-1 + GIP |
| Route | Weekly injection (single pen) | Weekly injection |
| Max weight loss (Phase 3) | 22.7% (REDEFINE 1) | 20.9% (SURMOUNT-1) |
| Head-to-head result | 22.2% (lost to tirzepatide) | 25.3% (won head-to-head) |
| Non-inferiority met? | No | Winner |
| T2D weight loss | 15.7% (REDEFINE 2) | ~12-15% (SURMOUNT-2) |
| CV outcomes data | None (semaglutide component has SELECT) | Pending (SURPASS-CVOT) |
| FDA status | NDA filed Dec 2025, under review | Approved (Nov 2023) |
| Availability | Not available | Available now |
| Pricing | Unknown | $299-$449/mo self-pay (LillyDirect) |
| Medicare coverage | TBD | ~$50/mo (Bridge program) |
| Insurance coverage | TBD | Broadly established |
How do CagriSema and tirzepatide work differently?
CagriSema combines semaglutide (GLP-1 agonist) with cagrilintide (amylin analog) to suppress appetite through two separate brain pathways. Tirzepatide is a single molecule that activates both GLP-1 and GIP receptors, which drives improved metabolic efficiency alongside appetite suppression — and that difference likely explains why tirzepatide won the REDEFINE 4 head-to-head trial.
CagriSema: GLP-1 + Amylin
CagriSema combines two components in one injection:
-
Semaglutide (GLP-1 receptor agonist) — the same molecule in Wegovy/Ozempic. Reduces appetite, slows gastric emptying, improves blood sugar, demonstrated cardiovascular benefit in SELECT trial.
-
Cagrilintide (long-acting amylin analog) — targets amylin receptors in the brain's area postrema and hypothalamus. Amylin is naturally released from the pancreas after meals and signals satiety through a pathway distinct from GLP-1. Cagrilintide extends this effect for weekly dosing.
The theory: By targeting two different appetite-regulation pathways simultaneously, CagriSema produces greater satiety and weight loss than either component alone. Novo Nordisk described this as a "1+1=3" effect during development.
Tirzepatide: GLP-1 + GIP
Tirzepatide is a single molecule that activates two receptors:
- GLP-1 receptor — appetite reduction, blood sugar control, cardiovascular benefit (same as semaglutide)
- GIP receptor — enhances insulin sensitivity, improves fat metabolism, and appears to amplify the weight-loss effects of GLP-1 agonism
The advantage: GIP receptor activation drives metabolic improvements that go beyond appetite suppression — improved insulin sensitivity, enhanced fat oxidation, and potentially better body composition. Tirzepatide's dual action in a single molecule also simplifies manufacturing and delivery.
Which Mechanism Is Better?
REDEFINE 4 answered this question directly: tirzepatide's GLP-1/GIP dual agonism produced more weight loss than CagriSema's GLP-1/amylin combination in a head-to-head comparison. The 25.3% vs. 22.2% difference was statistically significant and clinically meaningful.
However, mechanism differences may matter beyond the weight loss number — for liver fat, cardiovascular risk, diabetes management, or specific patient populations. These nuances are still being studied.
What did the REDEFINE 4 head-to-head trial show?
Tirzepatide won. CagriSema produced 22.2% weight loss; tirzepatide produced 25.3%. CagriSema failed to meet the pre-specified non-inferiority margin — meaning the trial could not confirm CagriSema was even as good as tirzepatide.
REDEFINE 4 is the pivotal study in this comparison because it's the only trial that directly compared these medications. Here's what happened:
Design:
- ~1,500 adults with obesity (BMI ≥30 or ≥27 with comorbidity)
- Randomized to CagriSema vs. tirzepatide (at maximum tolerated doses)
- 72-week treatment period
- Primary endpoint: non-inferiority of CagriSema vs. tirzepatide for percent body weight change
Results:
| Outcome | CagriSema | Tirzepatide |
|---|---|---|
| Mean weight loss | 22.2% | 25.3% |
| Non-inferiority met? | No | Winner |
| Difference | -3.1 percentage points | — |
Why this matters:
-
CagriSema failed its primary endpoint. The trial was designed to show CagriSema was "at least as good as" tirzepatide. It was not. This is a meaningful regulatory and commercial setback.
-
Tirzepatide outperformed by 3.1 percentage points. For a 250-lb patient, that's approximately 8 additional pounds of weight loss with tirzepatide — clinically relevant.
-
This complicates CagriSema's positioning. If CagriSema is approved, it enters the market as a medication that lost its head-to-head comparison with an already-available competitor. That's a difficult marketing position.
-
For patients, the implication is clear: If your primary goal is maximum weight loss and you can access tirzepatide, the REDEFINE 4 data favors tirzepatide.
How do CagriSema and tirzepatide compare across all trial data?
When all trial data is laid out, CagriSema's standalone result (22.7% in REDEFINE 1) looks competitive with tirzepatide's SURMOUNT-1 result (20.9%) — but REDEFINE 4 resolved that apparent tie. In the same patients, tirzepatide produced 25.3% versus CagriSema's 22.2%.
| Trial | Medication | Weight Loss | Duration | Population |
|---|---|---|---|---|
| REDEFINE 1 | CagriSema | 22.7% | 68 weeks | Obesity |
| REDEFINE 2 | CagriSema | 15.7% | 68 weeks | T2D + obesity |
| REDEFINE 4 | CagriSema | 22.2% | 72 weeks | Obesity (head-to-head) |
| REDEFINE 4 | Tirzepatide | 25.3% | 72 weeks | Obesity (head-to-head) |
| SURMOUNT-1 | Tirzepatide | 20.9% | 72 weeks | Obesity |
| SURMOUNT-2 | Tirzepatide | 12.8-14.7% | 72 weeks | T2D + obesity |
| SURMOUNT-4 | Tirzepatide | ~20% | 88 weeks | Obesity (with run-in) |
Important context: CagriSema's REDEFINE 1 result (22.7%) is higher than tirzepatide's SURMOUNT-1 result (20.9%), which initially made CagriSema look competitive. But cross-trial comparisons are unreliable — different patient populations, protocols, and sites introduce confounding variables. REDEFINE 4 resolved this by putting them in the same trial, and tirzepatide won.
How do CagriSema and tirzepatide compare on side effects?
CagriSema has a worse GI side effect profile than tirzepatide across every category — higher nausea (40-45% vs 24-33%), more vomiting, and more injection site reactions. Tirzepatide delivers more weight loss with better tolerability, which is a decisive advantage for most patients.
| Side Effect | CagriSema (REDEFINE data) | Tirzepatide (SURMOUNT data) |
|---|---|---|
| Nausea | 40-45% | 24-33% |
| Diarrhea | 25-30% | 17-23% |
| Vomiting | 15-20% | 8-12% |
| Constipation | 10-15% | 6-12% |
| Injection site reactions | 10-15% | ~5% |
| Discontinuation (adverse events) | ~7-10% | ~5-7% |
CagriSema has a worse GI side effect profile. Nausea, diarrhea, and vomiting rates are all higher than tirzepatide. This is likely because CagriSema combines two drugs — each with its own GI effects — while tirzepatide is a single molecule. The amylin component (cagrilintide) adds its own nausea and gastric slowing on top of the semaglutide foundation.
Higher injection site reactions (10-15% vs ~5%) are also notable. This may be related to the combination formulation or the delivery device.
How do CagriSema and tirzepatide compare on dosing?
Both medications use a once-weekly injection with a ~4-month gradual titration schedule. CagriSema escalates two components simultaneously in a single combination pen; tirzepatide escalates a single molecule in a standard auto-injector.
| Factor | CagriSema | Tirzepatide (Zepbound) |
|---|---|---|
| Starting dose | Cagrilintide 0.16 mg + semaglutide 0.25 mg | 2.5 mg |
| Dose steps | 5 steps | 5 steps |
| Titration length | ~17 weeks to maintenance | 16-20 weeks |
| Maintenance dose | Cagrilintide 2.4 mg + semaglutide 2.4 mg | 10 mg or 15 mg |
| Injection frequency | Once weekly | Once weekly |
| Injection device | Single combination pen | Auto-injector pen |
Dosing schedules are broadly similar — both require ~4 months to reach full therapeutic dose with gradual escalation.
How do CagriSema and tirzepatide compare on cost and access?
Tirzepatide is available now at $299-449/month self-pay through LillyDirect or as low as $25/month with eligible commercial insurance. CagriSema has no pricing, no approval, and no availability. For patients asking "is CagriSema worth it" — the question can't be fully answered until it's actually on the market.
Tirzepatide (Available Now)
| Access Path | Monthly Cost |
|---|---|
| LillyDirect (self-pay) | $299-$449/mo |
| Medicare Part D (Bridge program) | ~$50/mo |
| Commercial insurance (with copay card) | $25-$50/mo (if covered) |
| Employer plans | Varies — 43% of large employers now cover |
Tirzepatide has 3+ years of market presence, broad PBM formulary coverage, established prior authorization pathways, and multiple cost-reduction programs. Insurance access is mature.
CagriSema (Not Yet Available)
- Pricing: Not announced
- Insurance: No coverage — not approved
- Availability: None — pending FDA decision
If approved, CagriSema will need to establish insurance coverage from scratch. Initial formulary negotiations could take 6-12 months post-approval. Launch pricing will likely be competitive with Zepbound ($300-500/mo range), but the REDEFINE 4 non-inferiority miss may weaken Novo Nordisk's negotiating position with PBMs and payers.
When might CagriSema still be the better choice over tirzepatide?
CagriSema may be preferred for patients who can't tolerate tirzepatide, those who responded well to semaglutide and want more efficacy without switching drug classes, or patients where the semaglutide component's cardiovascular outcomes data (SELECT trial) matters clinically.
Despite losing the head-to-head, CagriSema may be preferred in specific situations:
1. Patients who don't tolerate tirzepatide
Some patients experience intolerable side effects with tirzepatide's GIP component. CagriSema works through a completely different secondary mechanism (amylin vs. GIP). Switching to a different mechanism class is a valid clinical strategy.
2. Patients who respond better to semaglutide
CagriSema builds on the semaglutide foundation. Patients who responded well to Wegovy but want more weight loss might prefer CagriSema over switching to a completely different molecule (tirzepatide).
3. Cardiovascular risk patients
Semaglutide has cardiovascular outcomes data (SELECT trial: 20% MACE reduction). CagriSema contains the same semaglutide molecule. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) has not reported yet. For patients where cardiovascular benefit is a priority, CagriSema may offer a more proven CV profile.
4. Type 2 diabetes patients
CagriSema's REDEFINE 2 data (15.7% weight loss in T2D) compares favorably to tirzepatide's SURMOUNT-2 data (12.8-14.7% in T2D). In the diabetes population, CagriSema may hold a narrower — or potentially no — disadvantage. A head-to-head T2D trial would be needed to confirm.
5. Formulary and pricing dynamics
If Novo Nordisk prices CagriSema aggressively to compensate for the REDEFINE 4 result, it could become a more affordable option than Zepbound for some patients and payers.
When is tirzepatide the clear winner over CagriSema?
For most patients, tirzepatide is the clear winner: more weight loss, better tolerability, available now, established insurance coverage, and years of real-world data. The "CagriSema vs tirzepatide which is better" question has a direct answer from the REDEFINE 4 trial — tirzepatide won.
1. Maximum weight loss is the priority
REDEFINE 4 is unambiguous: tirzepatide produces more weight loss (25.3% vs. 22.2%). If your primary goal is maximizing weight loss, tirzepatide is the evidence-based choice.
2. You want treatment now
Tirzepatide has been available since November 2023. CagriSema is not approved, has no announced timeline, and will need months of post-approval formulary negotiation before broad access. Starting tirzepatide now means results now.
3. Side effect tolerance matters
Tirzepatide has lower rates of nausea, diarrhea, and vomiting than CagriSema. If GI tolerability is a concern, the data favors tirzepatide.
4. Insurance coverage
Tirzepatide has mature insurance infrastructure — PBM formulary placement, established PA pathways, Medicare Bridge coverage. CagriSema will start from zero.
5. Real-world evidence
Tirzepatide has 3+ years of post-market data, millions of prescriptions filled, and extensive real-world safety and effectiveness evidence. CagriSema has trial data only.
What is the bottom line on CagriSema vs tirzepatide?
For most patients considering these two medications, the answer is straightforward: tirzepatide is the better-supported choice.
It produces more weight loss in head-to-head comparison, has a better side effect profile, is available today, has established insurance coverage, and has years of real-world evidence. CagriSema lost the only direct comparison and is not yet approved.
CagriSema may still find a meaningful role — particularly for patients who don't tolerate tirzepatide, those who prefer to stay in the semaglutide family, those who prioritize cardiovascular outcomes data, or if Novo Nordisk prices it aggressively. But as of April 2026, tirzepatide is the drug with both the data and the availability advantage.
Frequently Asked Questions
Is CagriSema better than tirzepatide for weight loss? No. In the head-to-head REDEFINE 4 trial, tirzepatide produced 25.3% weight loss versus CagriSema's 22.2%. CagriSema failed to meet the non-inferiority endpoint, meaning tirzepatide is the statistically superior medication in the only direct comparison that exists.
Should I wait for CagriSema or start tirzepatide now? Start tirzepatide now. CagriSema is not FDA approved, has no confirmed launch date, and lost its head-to-head trial against tirzepatide. Starting tirzepatide today delivers proven results immediately — and you can always switch later if CagriSema offers specific advantages after approval.
Why did CagriSema lose to tirzepatide in REDEFINE 4? CagriSema's GLP-1 + amylin mechanism did not match tirzepatide's GLP-1 + GIP dual agonism for weight loss. GIP receptor activation appears to provide metabolic benefits — including improved fat metabolism and insulin sensitivity — that amylin does not replicate. The 3.1 percentage point gap was statistically significant and clinically meaningful.
What does CagriSema vs tirzepatide cost? Tirzepatide (Zepbound) costs $299-449/month self-pay through LillyDirect, or as low as $25/month with eligible commercial insurance. CagriSema pricing has not been announced. Analysts estimate $1,200-1,500/month at launch, though the REDEFINE 4 non-inferiority miss may pressure Novo Nordisk toward competitive pricing.
Is CagriSema worth it compared to tirzepatide? For most patients, no — tirzepatide is available now, produced more weight loss in the head-to-head trial, has better tolerability, and has years of real-world evidence. CagriSema may be worth considering if you can't tolerate tirzepatide or want to stay in the semaglutide ecosystem. But as a first choice, tirzepatide has the stronger evidence base.
What is the main difference between CagriSema and tirzepatide (Zepbound)? CagriSema combines semaglutide with an amylin analog (cagrilintide) to suppress appetite through two GLP-1-distinct pathways. Tirzepatide activates GLP-1 and GIP receptors simultaneously, which adds metabolic efficiency benefits. Tirzepatide is approved and available; CagriSema is pending FDA review with no confirmed timeline.
Related Guides
- CagriSema Patient Guide — Complete CagriSema overview, REDEFINE trial data, timeline
- CagriSema PDUFA Decision Guide — Scenario planning for FDA decision
- CagriSema vs Wegovy — Same-manufacturer comparison
- CagriSema vs Retatrutide — Next-gen pipeline comparison
- CagriSema vs Orforglipron — Premium vs. affordable comparison
- CagriSema Dosing Guide — Titration schedule and dose details
- CagriSema Side Effects Guide — Side effect management
- GLP-1 Medication Comparison Chart 2026 — All medications compared
- Best GLP-1 Weight Loss Programs — Provider comparison for starting treatment now
Where to Get These Medications
Compare providers offering GLP-1 medications.
Related Guides
Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care
The best telehealth providers for tirzepatide in 2026, ranked by price, protocol, and care quality. From $278/month compounded to brand Zepbound via insurance. No provider paid for placement.
Read guide →CagriSema Dosing Guide: Titration Schedule, Dose Steps & What to Expect
Complete CagriSema dosing and titration guide based on REDEFINE trial protocols. Cagrilintide + semaglutide dose steps, injection schedule, and how CagriSema dosing compares to Wegovy and Zepbound.
Read guide →CagriSema Launch Day Patient Guide: What to Do Now That It's Here
CagriSema — the cagrilintide/semaglutide combination — has received FDA approval. This launch day guide covers everything patients need to know: how to get it, expected pricing, insurance strategies, how it compares to existing options, and a step-by-step action checklist.
Read guide →CagriSema: The Semaglutide + Cagrilintide Combination — Patient Guide
Complete guide to CagriSema — Novo Nordisk's cagrilintide + semaglutide combination with 23% weight loss. NDA filed December 2025, under FDA review with no PDUFA date disclosed. Full status update.
Read guide →